Background: The most recent immunotherapy, used in the treatment of non-small cell lung malignancy (NSCLC), uses monoclonal antibodies directed against programmed death ligand 1 (PD-L1) to inhibit its interaction with the PD-1 receptor. = 0.0206), but not between AC and Rabbit Polyclonal to MRPS34 SCC (U-Mann-Whitney, = 0.0780) (Physique 2). The highest level of expression… Continue reading Background: The most recent immunotherapy, used in the treatment of non-small